Embecta names Devdatt Kurdikar as board chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
embecta names new Chairman of the Board and Lead Independent Director
February 11, 2026 4:10 PM ESTPARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the Board) of embecta has elected Devdatt Dev Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board due to several commitments outside of his service to the Company.
Kurdikar, 57, joined BD... More
